Copyright 2008 Medical News Today Latest Irritable-Bowel Syndrome News From Medical News Today. http://www.medicalnewstoday.com/sections/ibs/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Mon, 12 May 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/106967.php The symptoms of IBS and coeliac disease can often be very similar as a result the diagnosis of coeliac disease can be delayed or missed and IBS is misdiagnosed. Tue, 06 May 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/106300.php Theories abound about the cause of Irritable Bowel Disease (IBD): Diet? Stress? Perhaps an infection? On the other hand, is it possible depression could be triggering the disease in some of the 20 per cent of Canadians suffering from this digestive system disorder? New research conducted by scientists in McMaster University's Intestinal Disease Research Program suggests it's highly likely that in some patients depression is wreaking havoc on the gut. Fri, 02 May 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/105999.php Researchers at Mattel Children's Hospital UCLA have found that low-dose antidepressant therapy can significantly improve the overall quality of life for adolescents suffering from irritable bowel syndrome, or IBS.The syndrome affects 6 percent of middle school students and 14 percent of high school kids in the United States. Wed, 30 Apr 2008 16:00:00 PDT http://www.medicalnewstoday.com/articles/105862.php Sucampo Pharmaceuticals, Inc., (NASDAQ: SCMP, Sucampo Pharmaceuticals) and Takeda Pharmaceutical Company Limited (TSE: 4502, Takeda) and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Wed, 30 Apr 2008 03:00:00 PDT http://www.medicalnewstoday.com/articles/105837.php The U.S. Food and Drug Administration approved Amitiza (lubiprostone) for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adult women aged 18 and over. There is currently no prescription drug therapy for IBS-C. With this approval, Amitiza becomes the only FDA-approved medical treatment for IBS-C available in the United States. Irritable bowel syndrome is a disorder characterized by cramping, abdominal pain, bloating, constipation, and diarrhea. Thu, 10 Apr 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/103387.php Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4) announced that through its wholly-owned subsidiary, Synergy Pharmaceuticals, Inc. it filed an IND on April 2, 2008 with the FDA for SP-304 (also called Guanilib) for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. SP-304 is an analog of uroguanylin, a natural hormone produced in the gastro-intestinal (GI) tract that is a key regulator of intestinal function. Thu, 20 Mar 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/101129.php Food For Life Baking Company of Corona, California is voluntarily recalling 2,241 cases of Spelt Bread (UPC# 07347200168) because they contain spelt grain which is known to be a hybrid of wheat. People who have allergies to wheat or those with Celiac Disease may run the risk of a serious or life threatening allergic reaction if they consume spelt products. The recalled products were sold nationwide through health food distributors and natural food retailers. Sat, 02 Feb 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/95986.php UCLA and University of North Carolina researchers have found that women with irritable bowel syndrome (IBS) who have experienced sexual and/or physical abuse may have a heightened brain response to pain that makes them more sensitive to abdominal discomfort. IBS is a condition that affects 10 to 15 percent of the population and causes gastrointestinal discomfort along with diarrhea, constipation or both. Thu, 24 Jan 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/94929.php Adults with allergy symptoms report a high incidence of Irritable Bowel Syndrome (IBS), suggesting a link between atopic disorders and IBS according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).In a study of 125 adults, Mary C. Tobin, M. Tue, 15 Jan 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/93942.php Irish scientists have discovered a new potential therapeutic approach to Inflammatory Bowel Disease (IBD), a chronic debilitating disease involving inflammation of the intestine which affects more than 15,000 people in Ireland and millions of people worldwide. People suffering from IBD can experience an array of symptoms ranging from mild discomfort to debilitating disease requiring surgical removal of large parts of the intestine. Fri, 09 Nov 2007 13:00:00 PDT http://www.medicalnewstoday.com/articles/88332.php Dynogen Pharmaceuticals, Inc. announced that the first patients have been dosed in a Phase 2b trial of DDP733 (pumosetrag) as a treatment for irritable bowel syndrome with constipation (IBS-c). This DDP733 Phase 2b trial is a randomized, double-blind, placebo controlled study that is enrolling female patients with IBS-c at multiple centers in the U.S. and Canada. Thu, 08 Nov 2007 01:00:00 PDT http://www.medicalnewstoday.com/articles/88037.php Fibromyalgia is a chronic condition characterized by widespread pain in your muscles, ligaments and tendons, as well as fatigue and multiple tender points. A new feature on mayoclinic.com provides users with information regarding the process for diagnosing fibromyalgia. Because there is no single, specific diagnostic laboratory test, diagnosis can be difficult. Wed, 31 Oct 2007 01:00:00 PDT http://www.medicalnewstoday.com/articles/87143.php For the first time a once daily dosing regime of mesalazine (Pentasa(R) granules) has proven to be statistically superior to twice daily dosing for the effective maintenance of remission in patients suffering from mild to moderate ulcerative colitis (UC), finds a trial presented at the 15th United European Gastroenterology Week (UEGW) congress. Tue, 16 Oct 2007 06:00:00 PDT http://www.medicalnewstoday.com/articles/85656.php Those who suffer from common functional gastrointestinal disorders face work productivity losses and impairments in daily activity that amount to the loss of at least one day of work in a 40-hour workweek, according to a new study presented at the Annual Scientific Meeting of the American College of Gastroenterology.Functional gastrointestinal disorders are associated with impaired quality of life and are among the most common causes of work-related absenteeism. Tue, 16 Oct 2007 06:00:00 PDT http://www.medicalnewstoday.com/articles/85646.php Colorectal screening remains essential for those with IBDResearchers found that mesalamine use among patients with inflammatory bowel disease was associated with a decrease in incidence of colorectal cancer when comparing cases and controls. Tue, 16 Oct 2007 05:00:00 PDT http://www.medicalnewstoday.com/articles/85642.php A new analysis of randomized controlled trials evaluating probiotics in the treatment of irritable bowel syndrome (IBS) has found that Bifantis®, Bifidobacterium infantis 35624, the sole ingredient in Align® (manufactured by Procter & Gamble), is the only probiotic currently able to demonstrate significant improvement in IBS symptoms based upon a properly designed research study. Tue, 16 Oct 2007 00:00:00 PDT http://www.medicalnewstoday.com/articles/85561.php A new analysis of randomized controlled trials evaluating probiotics in the treatment of irritable bowel syndrome (IBS) has found that Bifantis(R), Bifidobacterium infantis 35624, the sole ingredient in Align(R) (manufactured by Procter & Gamble), is the only probiotic currently able to demonstrate significant improvement in IBS symptoms based upon a properly designed research study. Tue, 18 Sep 2007 00:00:00 PDT http://www.medicalnewstoday.com/articles/82740.php Sucampo Pharmaceuticals, Inc., (Nasdaq: SCMP) announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA). Sucampo Pharmaceuticals currently anticipates a decision from the FDA in the second quarter of 2008. Wed, 22 Aug 2007 00:00:00 PDT http://www.medicalnewstoday.com/articles/80297.php Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) presented data today describing the structure-activity relationship (SAR) of a class of internally-developed compounds that includes LX1031 and other compounds under evaluation by the company as potential treatments for irritable bowel syndrome (IBS) and other gastrointestinal disorders. LX1031 is currently under evaluation in a Phase 1b clinical trial in healthy volunteers. Thu, 09 Aug 2007 00:00:00 PDT http://www.medicalnewstoday.com/articles/79179.php Irritable Bowel Syndrome (IBS) is a disorder of bowel function. Patients who suffer from irritable bowel syndrome have abdominal pain or discomfort accompanied by changes in bowel habits such as constipation or diarrhea (or both). Additional symptoms of IBS include abdominal bloating, loss of appetite, and general malaise.IBS is an extremely common disorder. Studies have estimated the prevalence in the United States to be somewhere between 15% and 20% of the entire population. Sun, 29 Jul 2007 09:00:00 PDT http://www.medicalnewstoday.com/articles/77952.php The use of biologic agents for the treatment of inflammatory bowel disease (IBD) may benefit patients, but doctors need to consider the potential associated side effects in determining treatment course, according to a consensus paper published in this month's issue of Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. Sat, 28 Jul 2007 00:00:00 PDT http://www.medicalnewstoday.com/articles/78120.php In cooperation with the US Food and Drug Administration (FDA), Novartis has established a restricted access program for Zelnorm(R) (tegaserod maleate) so that patients in need of this medicine can be considered for treatment. Tue, 17 Jul 2007 03:00:00 PDT http://www.medicalnewstoday.com/articles/76794.php Sucampo Pharmaceuticals, Inc., (Sucampo Pharmaceuticals) has announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C). Fri, 13 Jul 2007 00:00:00 PDT http://www.medicalnewstoday.com/articles/76702.php Sucampo Pharmaceuticals, Inc., (Sucampo Pharmaceuticals) today announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C). Sat, 07 Jul 2007 01:00:00 PDT http://www.medicalnewstoday.com/articles/76157.php Statin drugs which are widely prescribed to prevent heart disease may emerge as a future treatment for Crohn's disease, an inflammatory bowel condition, a scientist said last Tuesday. Surgical research fellow Dr. John Burke was addressing the Association of Coloproctology meeting in Glagow about research which is reinforcing the idea that statins are becoming 'the aspirin of the 21st Century'.